(Q36417749)

14 August 2017

Cost, coverage, and comparative effectiveness research: the critical issues for oncology (English)

1 reference

14 August 2017

Steven D Pearson

1

1 reference

PMC publication ID

3504329

14 August 2017

language of work or name

English

0 references

publication date

15 October 2012

1 reference

Journal of Clinical Oncology

14 August 2017

1 reference

14 August 2017

30

1 reference

14 August 2017

34

1 reference

14 August 2017

4275-4281

1 reference

Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And Reimbursement

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

American Society of Clinical Oncology guidance statement: the cost of cancer care

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Comparative effectiveness research and evidence-based health policy: experience from four countries

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Systematic review: reliability of compendia methods for off-label oncology indications.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Medicare's requirement for research participation as a condition of coverage: is it ethical?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

What we talk about when we talk about health care costs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Developing a center for comparative effectiveness information

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

Delivering affordable cancer care in high-income countries

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504329

21 October 2018

A menu without prices

1 reference

12 December 2020

Limits on Medicare's ability to control rising spending on cancer drugs

1 reference

12 December 2020

Many new cancer drugs in the United Kingdom are facing negative NICE rulings

1 reference

12 December 2020

Cancer therapy costs influence treatment: a national survey of oncologists

1 reference

12 December 2020

Cost-effectiveness information: yes, it's important, but keep it separate, please!

1 reference

12 December 2020

Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research

1 reference

12 December 2020

Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals

1 reference

12 December 2020

Off-label use of oncology drugs: the need for more data and then some

1 reference

12 December 2020

Coverage options for promising technologies: Medicare's 'coverage with evidence development'

1 reference

12 December 2020

Tier 4 drugs and the fraying of the social compact

1 reference

12 December 2020

US moves to improve health decisions

1 reference

12 December 2020

Comparative-effectiveness research--implications of the Federal Coordinating Council's report

1 reference

12 December 2020

Information on cost-effectiveness: an essential product of a national comparative effectiveness program

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2012.42.6601

1 reference

14 August 2017

1 reference

PMC publication ID

3504329

14 August 2017

PubMed publication ID

23071229

1 reference

PMC publication ID

3504329